Gout meds

Gout treatment and pharmacogenetics

Also known as: Urate-lowering therapy, Hyperuricemia treatment

1 medication 1 brand product ABCG2

Why pharmacogenetics matter for gout treatment

Allopurinol is the workhorse of chronic gout treatment. The pharmacogenetic angle Gene2Rx covers is ABCG2: reduced-function carriers respond less to allopurinol and often need higher doses or a switch to febuxostat. Patients of East Asian, South Asian, or African ancestry should also be aware that HLA-B*58:01 is a separate risk factor for severe allopurinol skin reactions. That allele isn't tested by Gene2Rx and is offered as a separate clinical test.

ABCG2 reduced-function carriers often need higher allopurinol doses to reach the under-6 mg/dL urate target, or a switch to febuxostat.

Key gene in this class

ABCG2

ATP-Binding Cassette Subfamily G Member 2 (BCRP)

ABCG2 is a transporter that moves urate and several drugs out of cells. The Q141K variant (rs2231142) is common, particularly in East Asian populations, and reduces transporter function. Carriers have …

Medications in this class with pharmacogenetic guidelines

Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.

Allopurinol ABCG2

Brand products in the Gout meds class

Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.

Zyloprim

allopurinol

Which gout meds is right for your genetics?

This page covers the pharmacogenetics of gout treatment in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.

Get your report Look up a medication

Informational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.